Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 512,000	$ 655,000
Accounts receivable	210,000	257,000
Inventories, net of allowance	26,000	26,000
Prepaid expenses and other current assets	34,000	17,000
Total current assets	782,000	955,000
In-process research and development (Note 8)	1,893,000	1,893,000
Equipment, net of depreciation	110,000	126,000
Other non-current assets	35,000	35,000
Right-of-use, operating lease, net of amortization	399,000
Deferred offering cost	176,000	176,000
Total assets	3,395,000	3,185,000
Current liabilities:
Accounts payable and accrued expenses	631,000	501,000
Notes payable	490,000	400,000
Line of credit	430,000	430,000
Convertible notes payable	2,072,000	1,365,000
Discount on convertible notes payable, and line of credit, net of amortization	(646,000)	(205,000)
Lease liability	116,000
Customer deposit	32,000
Total current liabilities	3,125,000	2,491,000
Long-term liabilities:
Convertible notes and note payable	235,000	285,000
Clyra Medical note payable (Note 8)	1,242,000	1,292,000
Discount on convertible notes payable, net of amortization	(105,000)	(118,000)
Lease liability	283,000
Total long-term liabilities	2,063,000	1,817,000
Total liabilities	5,188,000	4,308,000
COMMITMENTS, CONTINGENCIES (Note 11)
STOCKHOLDERS’ EQUITY (DEFICIT):
Preferred Series A, $.00067 Par Value, 50,000,000 Shares Authorized, -0- Shares Issued and Outstanding, at December 31, 2018 and March 31, 2019, respectively.
Common stock, $.00067 Par Value, 400,000,000 Shares Authorized, 141,466,071 and 144,473,453 Shares Issued, at December 31, 2018 and March 31, 2019, respectively.	97,000	95,000
Additional paid-in capital	112,556,000	110,222,000
Accumulated other comprehensive loss	(94,000)	(90,000)
Accumulated deficit	(114,641,000)	(111,723,000)
Total BioLargo Inc. and Subsidiaries stockholders’ equity (deficit)	(2,082,000)	(1,496,000)
Non-controlling interest (Note 8)	289,000	373,000
Total stockholders’ equity (deficit)	(1,793,000)	(1,123,000)
Total liabilities and stockholders’ equity (deficit)	3,395,000	3,185,000
Scion Acquisition [Member] | Clyra Acquisition, Common Stock Redeemable for BioLargo Common Shares [Member]
Long-term liabilities:
Liability to Clyra Medical shareholder (Note 8)	643,000	643,000
Convertible Notes Issued by Clyra Medical Maturing on June 17, 2020 [Member]
Long-term liabilities:
Clyra Medical note payable (Note 8)	1,007,000	$ 1,007,000
Convertible Notes Issued by Clyra Medical Maturing on June 17, 2020 [Member] | Scion Acquisition [Member]
Long-term liabilities:
Clyra Medical note payable (Note 8)	$ 1,007,000